The $350m fund will provide capital for Gingko spinoffs and has attracted limited partners including Viking Global Investors, General Atlantic and Cascade Investment.

First Round's inaugural cohort includes a manga comic translation tool developer and a company working on synthetic options for creating salmon.

SoftBank Vision Fund-backed immunology therapy developer Vir will float at the bottom of its range, having raised in excess of $820m in VC funding in roughly three years.

University of Colorado-founded IM Therapeutics has received $10m from investors including the university's Healthcare Innovation Fund to advance a treatment for type 1 diabetes.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Stanford University general counsel Debra Zumwalt reportedly hoped to prevent further legal filings against her and other Stanford trustees.

The Vantage Ventures incubator will aim to realise West Virginia University's goal of making West Virginia a startup powerhouse.

Johannes Gutenberg University of Mainz's cancer therapy developer raised $150m despite reducing the number of shares in the IPO and floating beneath its range.

The Eli Lilly, Pfizer and Sanofi-backed cancer therapy developer raised $150m despite reducing the number of shares in the IPO and floating beneath its range.

LabCentral 238 has secured $12.5m from founding sponsor Astellas, which will also provide capital for LabCentral's existing incubator.